Source link : https://newshealth.biz/health-news/very-impressive-survival-with-combo-in-first-line-prostate-cancer-study/
(MedPage Today) — SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring… Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120096 Author : Publish date : 2026-02-27 22:43:00 Copyright for syndicated content belongs to the linked Source.
The post ‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study first appeared on News Health.
—-
Author : News Health
Publish date : 2026-02-27 22:43:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8